Elutia Inc
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Elutia Inc. (Nasdaq: ELUT) develops and commercializes drug-eluting biomatrix technologies to enhance compatibility between implantable medical devices and patients, focusing on reducing post-surgical complications such as infections, device migration, erosion, and fibrosis; its core products include SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction in applications such as breast reconstruction, sports medicine, hernia repair, and trauma; EluPro and CanGaroo bioenvelopes, antibiotic-eluting acellular envelopes for stabilizing cardiac implantable electronic devices like pacemakers and defibrillators, as well as neurostimulators in electrophysiology and neuromodulation; and cardiovascular solutions such as ProxiCor for cardiac tissue repair and pericardial closure, Tyke for neonatal and infant cardiac structure repair, and VasCure for peripheral vasculature reconstruction. The company operates in the Device Protection, Women's Health, and Cardiovascular segments, serving hospitals and healthcare facilities in the United States through direct sales, commercial partners, independent agents, and distributors. Founded in 2015 and headquartered in Silver Spring, Maryland, Elutia previously operated as Aziyo Biologics, Inc., changing its name in September 2023. In September 2025, Elutia sold its BioEnvelope business, including EluPro and CanGaroo, to Boston Scientific Corporation for $88 million in cash, a transaction that closed on October 1, 2025, enabling debt elimination, resolution of orthobiologics litigation, and non-dilutive funding for its NXT-41 and NXT-41x drug-eluting biomatrix pipeline targeting the $1.5 billion U.S. breast reconstruction market; earlier in 2025, it secured a strategic partnership with Boston Scientific to accelerate EluPro adoption, signed two new group purchasing organization contracts, and raised $15 million through a registered direct offering while restructuring debt terms.
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
Elutia to Present at the 16th Annual LD Micro Invitational May 18th
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Elutia Regains Compliance with Nasdaq Listing Requirements
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Elutia (NASDAQ:ELUT) Shares Up 4.7% – Should You Buy?
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
Elutia (NASDAQ:ELUT) Director Purchases $26,000.00 in Stock